Bendamustine Hydrochloride

Chongqing Huapont Pharmaceutical Co. Ltd. 
HUAPONT - established in 1992 - is equipped with state-of-the-art facilities and a strong R&D force. It is dedicated primarily to the manufacturing and marketing of APIs as well as drug products for dermatology, fighting tuberculosis, and oncology.

Indication
Bendamustine Hydrochloride (Ribomustin^® MUNDIPHARMA and Treanda^® CEPHALON) is an antineoplastic alkylating agent. It is given intravenously as the hydrochloride for the treatment of chronic lymphocytic leukemia (CLL). It may also be used for non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), multiple myeloma (MM, Kahler’s disease), and breast cancer.

Market performance
Currently, the world-wide market volume of Ribomustin^® / Treanda^® is approximately USD 270 million. It is therefore considered a growing product with future blockbuster potential.

Patent situation
The regulatory authorities granted new data exclusivity to Ribomustin^®. Although there are no unexpired patents, the generic entry is hindered by the validity of the data exclusivity.

Advantages for general medicinal product manufacturers

• Availability of an active substance from an emergent Chinese active pharmaceutical ingredient manufacturer with strong growth, an attractive cost structure, as well as exceptional scientific expertise.
• The latter will be combined with the regulatory expertise and quality guarantee of a dependable, long-standing Swiss company.
• Particularly in fraught economic conditions, these are important criteria for a reliable integration of active pharmaceutical ingredients into our customers’ product portfolios.